Literature DB >> 16399144

PROactive study.

R R Holman, R Retnakaran, A Farmer, R Stevens.   

Abstract

Mesh：

Substances：

Year:  2006        PMID： 16399144     DOI： 10.1016/S0140-6736(06)67914-2

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  7 in total

Review 1.  Potential of glucose-lowering drugs to reduce cardiovascular events.

Authors:  Stuart W Zarich
Journal:  Curr Diab Rep       Date:  2009-02       Impact factor: 4.810

Review 2.  Antidiabetic agents and cardiovascular risk in type 2 diabetes.

Authors:  Stuart W Zarich
Journal:  Nat Rev Endocrinol       Date:  2009-07-28       Impact factor: 43.330

Review 3.  Does choice of antidiabetes therapy influence macrovascular outcomes?

Authors:  Stuart W Zarich
Journal:  Curr Diab Rep       Date:  2010-02       Impact factor: 4.810

4.  Development of life-expectancy tables for people with type 2 diabetes.

Authors:  Jose Leal; Alastair M Gray; Philip M Clarke
Journal:  Eur Heart J       Date:  2008-12-24       Impact factor: 29.983

5.  Temporal validation of the UKPDS outcomes model using 10-year posttrial monitoring data.

Authors:  Jose Leal; Alison J Hayes; Alastair M Gray; Rury R Holman; Philip M Clarke
Journal:  Diabetes Care       Date:  2012-12-28       Impact factor: 19.112

6.  Prediction of mortality and macrovascular complications in type 2 diabetes: validation of the UKPDS Outcomes Model in the Casale Monferrato Survey, Italy.

Authors:  E Pagano; A Gray; R Rosato; G Gruden; P Cavallo Perin; F Merletti; G Bruno
Journal:  Diabetologia       Date:  2013-05-17       Impact factor: 10.122

7.  Dipeptidyl peptidase-4 inhibitors improve arterial stiffness, blood pressure, lipid profile and inflammation parameters in patients with type 2 diabetes mellitus.

Authors:  Lea Duvnjak; Kristina Blaslov
Journal:  Diabetol Metab Syndr       Date:  2016-03-22       Impact factor: 3.320
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.